FindTrial
Sign In

Experimental group:Dapagliflozin

5 trials

Sponsors

Weishan People's Hospital, Xinqiao Hospital of Army Medical University, Taizhou First People's Hospital, The Second People’s Hospital of Foshan, Yuebei People's Hospital

Conditions

DiabetesHeart failure with preserved ejection fractionType 2 diabetes and nonalcoholic fatty liver diseasediabetestype 2 diabetes complicated with nonalcoholic fatty liver disease

Phase 1

Observation on the curative effect of dagglitazonein in the treatment of heart failure with preserved ejection fraction and its influence on hemodynamics
Active, not recruitingChiCTR2200063076
The Second People’s Hospital of FoshanHeart failure with preserved ejection fraction
Start: 2022-08-31Updated: 2023-04-12

Phase 4

To observe the effect of dapagliflozin on serum uric acid in Type 2 Diabetes Mellitus
RecruitingChiCTR2000040135
Weishan People's HospitalDiabetes
Start: 2020-12-01Updated: 2021-01-11
Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and nonalcoholic fatty liver disease
RecruitingChiCTR2100054612
Xinqiao Hospital of Army Medical UniversityType 2 diabetes and nonalcoholic fatty liver disease
Start: 2022-02-15Updated: 2022-11-28
Effect and mechanism of dapagliflozin on patients with type 2 diabetes complicated with nonalcoholic fatty liver disease
Active, not recruitingChiCTR2200064287
Yuebei People's Hospitaltype 2 diabetes complicated with nonalcoholic fatty liver disease
Start: 2022-10-01Updated: 2023-05-15

Unknown Phase

Clinical assessment of dapagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus: study protocol for a single-center, randomized, double-blind control trial
Active, not recruitingChiCTR2200058761
Taizhou First People's Hospitaldiabetes
Start: 2022-04-29Updated: 2024-01-22

Related Papers

Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease.
2023-09-0134 citations